Teva Says Wyeth Patent Deal Doesn't Step On Antitrust Law

Law360, New York (April 9, 2012, 8:47 PM EDT) -- Teva Pharmaceuticals USA Inc. on Friday moved to toss direct purchasers' claims in multiple class actions and individual suits accusing it of conspiring with Wyeth LLC to delay a generic antidepressant's entry into the market, arguing that settling patent litigation with Wyeth didn’t violate antitrust law.

In a series of coordinated class actions and individual suits brought by direct purchasers, Teva maintains it did not enter into a sham settlement with Pfizer Inc. unit Wyeth in order to delay the entry of Effexor XR into the...
To view the full article, register now.